Researchers at the University of Liverpool, lead by Dr. John Neoptolemos, have conducted the European Study Group for Pancreatic Cancer to "determine whether adjuvant chemotherapy (fluorouracil or gemcitabone) provides improved overall survival following resection." After 8 years of research, this study, considered to be the largest randomized trial ever conducted for this patient group(a total of 428 patients were observed), findings concluded that use of adjuvant chemotherapy can indeed improve survival in patients afflicted with periampullary cancers.
To read more about this study, click here.
Study mentioned: Neoptolemos JP et al. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: The ESPAC-3 periampullary cancer randomized trial. JAMA. 2012 Jul 11;308(2):147-56. PMID 22782416
No comments:
Post a Comment